Clinical Study On Intervention Of Ditan Granules On High Risk Population Of Stroke(Qi Deficiency And Phlegm Stagnation Syndrome)

Objective: The purpose of this research is to explore the primary prevention effect and safety of Ditan Granules in the intervention of high-risk population of stroke by observing the clinical efficacy of Ditan Granules in the intervention of high-risk population of stroke(Qi Deficiency and Phlegm Stagnation Syndrome).Methods: In this research,a prospective cohort study was conducted to collect the general information of high-risk population of stroke(Qi Deficiency and Phlegm Stagnation Syndrome)who met the inclusion and exclusion criteria.They were divided into control group and intervention group.The control group received routine primary prevention basic treatment,and the intervention group received Ditan granule plus routine primary prevention basic treatment.Using Epidata3.1 software to establish a database,double dual-machine independent data entry.SPSS 25.0 statistical software was used to analyze the data,and the changes of 10-year stroke risk,TCM syndrome score and blood lipid(total cholesterol(TC),triglyceride(TG),high density lipoprotein(HDL-C)and low density lipoprotein(LDL-C))、blood pressure in high-risk population of stroke(Qi Deficiency and Phlegm Stagnation Syndrome)were analyzed.Results: There were 131 cases in the intervention group and 201 cases in the control group in this research,making a total of 332.The top three risk factors in the included high-risk group for stroke were little physical activity,family history of stroke,and dyslipidaemia.There were 17.8% with no comorbid chronic diseases,36.7% with only 1comorbid chronic disease,28.3% with 2 comorbid chronic diseases and 17.2% with 3comorbid chronic diseases.Statistical analysis showed that the 10-year stroke risk,Qi deficiency syndrome,phlegm-damp syndrome score,TC,TG,LDL-C,systolic blood pressure and diastolic blood pressure decreased and HDL-C increased in the test group,and the difference was statistically significant(P < 0.01);in the control group,the 10-year stroke risk,Qi deficiency syndrome score,TC,LDL-C and systolic blood pressure and diastolic blood pressure decreased and HDL-C increased,and the difference was The difference was significant(P < 0.01)and the difference was significant(P < 0.05)for the decrease in TG level.In terms of reducing the 10-year stroke risk,Qi deficiency,TC and TG,the effect of the test group was better,and the difference was statistically significant(P < 0.05);in terms of reducing phlegm and dampness,LDL-C and increasing HDL-C,the test group was also superior,and there was a statistical difference(P < 0.01);in terms of reducing systolic blood pressure and diastolic blood pressure,the effect of the test group was not significantly different from that of the control group(P < 0.05).In terms of lowering systolic and diastolic blood pressure,there was no significant difference between the test group and the control group(P > 0.05).There were no significant abnormalities in safety indicators and no clinical adverse events during this study.Conclusion:1 More than 80% of people at high risk of stroke have a combination of 1 chronic disease or more,and more than three fifths of people have dyslipidaemia.2 A 3-month intervention in the trial and control groups showed that both groups improved the 10-year stroke risk,lipid levels,blood pressure levels and TCM clinical symptoms in patients at high risk of stroke.3 No adverse reactions or side effects occurred during the intervention,which is safe and has some value in clinical application and promotion.